Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.59 USD
Change Today -0.06 / -1.29%
Volume 677.2K
PTX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

pernix therapeutics holdings (PTX) Snapshot

Open
$4.69
Previous Close
$4.65
Day High
$4.75
Day Low
$4.57
52 Week High
03/11/15 - $12.88
52 Week Low
08/24/15 - $4.25
Market Cap
280.2M
Average Volume 10 Days
797.6K
EPS TTM
$-1.35
Shares Outstanding
61.0M
EX-Date
09/8/01
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PERNIX THERAPEUTICS HOLDINGS (PTX)

Related News

No related news articles were found.

pernix therapeutics holdings (PTX) Related Businessweek News

No Related Businessweek News Found

pernix therapeutics holdings (PTX) Details

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product. Its products also comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; Khedezla, a prescription medication for major depressive disorder. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women’s health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is headquartered in Morristown, New Jersey.

155 Employees
Last Reported Date: 03/2/15
Founded in 1996

pernix therapeutics holdings (PTX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $814.6K
Chief Financial Officer
Total Annual Compensation: $405.2K
Chief Operating Officer
Total Annual Compensation: $524.2K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $300.4K
Compensation as of Fiscal Year 2014.

pernix therapeutics holdings (PTX) Key Developments

Pernix Therapeutics Holdings, Inc. Announces the Completion of New Three-Year $50 Million Revolving Credit Facility with Wells Fargo

Pernix Therapeutics Holdings, Inc. announced the completion of a new three-year $50 million revolving credit facility with Wells Fargo. The new facility bears an interest rate of LIBOR plus 1.5% to LIBOR plus 2.0% versus the Company's prior revolving credit facility of LIBOR plus 7.5% with a 1.5% LIBOR floor, and is a substantial interest rate reduction. This new revolving credit facility reflects its commitment to lowering its cost of capital and provides the company with significant additional flexibility to support its growth strategy. The new revolving credit facility may be used for general corporate as well as strategic purposes, and is scheduled to mature in August 2018. As of June 30, 2015, Pernix had $7.9 million in outstanding borrowings under the Company's previous revolver. This new revolving credit facility replaces the company's previous credit facility.

Pernix Therapeutics Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Pernix Therapeutics Holdings, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the second quarter, net revenues were $46,977,000 against $17,382,000 a year ago. Loss from operations was $15,362,000 against $7,749,000 a year ago. Loss before income taxes benefit was $35,838,000 against $9,983,000 a year ago. Net loss was $32,235,000 against $6,234,000 a year ago. Net loss per share, diluted was $0.62 against $0.16 a year ago. EBITDA was $6,964,000 against LBITDA of $5,780,000 a year ago. Adjusted EBITDA was $7,946,000 against adjusted LBITDA of $3,954,000 a year ago. Adjusted net loss was $5,401,000 or $0.10 per basic and diluted share against $3,588,000 or $0.09 per basic and diluted share a year ago. On non-GAAP basis company reported a net loss of $5.4 million or $0.10 loss per share compared to $3.6 million or $0.09 loss per share for the same period last year. For the six months, net revenues were $80,866,000 against $36,434,000 a year ago. Loss from operations was $34,267,000 against $21,893,000 a year ago. Loss before income taxes benefit was $64,085,000 against $25,391,000 a year ago. Net loss was $55,909,000 against $15,776,000 a year ago. Net loss per share, basic and diluted was $1.23 against $0.42 a year ago. Adjusted net loss was $9,449,000 or $0.21 per basic and diluted share against $5,338,000 or $0.14 per basic and diluted share a year ago. EBITDA was $6,492,000 against LBITDA of $17,733,000 a year ago. Adjusted EBITDA was $12,537,000 against adjusted LBITDA of $5,906,000 a year ago. Net cash used in operating activities was $9,923,000 against $10,196,000 a year ago. Purchase of equipment was $726,000 against $419,000 a year ago. The company announced that it is revising its full year financial guidance based on the company's performance to date, and what Pernix believes is a reasonable estimate for the balance of the year 2015. The company now expects net revenue for 2015 to be in the range of $170 to $180 million. Adjusted EBITDA is expected to be in the range of $30 to $35 million.

Pernix Therapeutics Holdings, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Pernix Therapeutics Holdings, Inc. announced that they will report Q2, 2015 results at 8:30 AM, US Eastern Standard Time on Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTX:US $4.59 USD -0.06

PTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Interpharm Holdings Inc $0.0000 USD 0.00
OraSure Technologies Inc $5.23 USD -0.16
ProPhase Labs Inc $1.55 USD 0.00
SciClone Pharmaceuticals Inc $7.79 USD -0.19
Vanda Pharmaceuticals Inc $11.93 USD -0.25
View Industry Companies
 

Industry Analysis

PTX

Industry Average

Valuation PTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERNIX THERAPEUTICS HOLDINGS, please visit www.pernixtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.